SOX11/PRDX2 axis modulates redox homeostasis and chemoresistance in aggressive mantle cell lymphoma

Anna De Bolòs,Marta Sureda-Gómez,Maria Carreras-Caballé,Marta-Leonor Rodríguez,Guillem Clot,Silvia Beà,Eva Giné,Elias Campo,Patricia Balsas,Virginia Amador

DOI: https://doi.org/10.1038/s41598-024-58216-2

IF: 4.6

2024-04-04

Scientific Reports

Abstract:Mantle cell lymphoma (MCL) is an incurable B-cell neoplasm characterized by an aggressive behavior, short responses to conventional therapies and SOX11 overexpression, which is associated with aggressive disease features and inferior clinical outcome of patients. Oxidative stress is known to induce tumorigenesis and tumor progression, whereas high expression levels of antioxidant genes have been associated with chemoresistance in different cancers. However, the role of oxidative stress in MCL pathogenesis and the involvement of SOX11 regulating redox homeostasis in MCL cells are largely unknown. Here, by integrating gene set enrichment analysis of two independent series of MCL, we observed that SOX11+ MCL had higher reactive oxygen species (ROS) levels compared to SOX11− MCL primary tumors and increased expression of Peredoxine2 ( PRDX2 ), which upregulation significantly correlated with SOX11 overexpression, higher ROS production and worse overall survival of patients. SOX11 knockout (SOX11KO) significantly reduced PRDX2 expression, and SOX11KO and PRDX2 knockdown (PRDX2KD) had increased ROS levels and ROS-mediated tumor cell death upon treatment with drugs, compared to control MCL cell lines. Our results suggest an aberrant redox homeostasis associated with chemoresistance in aggressive MCL through SOX11-mediated PRDX2 upregulation, highlighting PRDX2 as promising target for new therapeutic strategies to overcome chemoresistance in aggressive MCLs.

multidisciplinary sciences

What problem does this paper attempt to address?

This paper aims to explore the role of the SOX11 and PRDX2 axis in aggressive mantle cell lymphoma (MCL), particularly how they regulate redox homeostasis and affect chemotherapy resistance. The study found that SOX11 overexpression is associated with higher levels of reactive oxygen species (ROS) and upregulation of PRDX2, while high PRDX2 expression is correlated with poorer overall survival in patients. Through gene knockout experiments, researchers discovered that SOX11 knockout significantly reduced PRDX2 expression, and both SOX11 knockout and PRDX2 knockdown increased ROS levels and ROS-mediated tumor cell death. These results suggest that in aggressive MCL, PRDX2 upregulation regulated by SOX11 leads to abnormal redox homeostasis, thereby promoting chemotherapy resistance, and indicate that PRDX2 may be a potential target for new therapeutic strategies to overcome chemotherapy resistance in aggressive MCL.